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Abstract
Background: Polyunsaturated fatty acids (PUFA) are thought to play important roles in
inflammation. The n-3 series is considered as anti-inflammatory, and some studies have reported
increased plasma n-3 polyunsaturated fatty acid pattern in chronic inflammatory conditions. In this
study we sought to clarify relationships of the levels of arachidonic acid and the polyunsaturated n-
3 fatty acid compositions of isolated LDL, HDL2 and HDL3 particles with matrix metalloproteinase-
9 (MMP-9), a marker of inflammation.
Results: The subjects were divided into two groups: those with lower and those with higher than
the median serum MMP-9 concentration. In all lipoprotein fractions, the mean percentage of
docosapentaenoic acid (C22:5n-3) was higher in the group of subjects with higher MMP-9 level than
in those with lower serum MMP-9 concentration (P < 0.01 for all). Likewise, the ratio of
docosapentaenoic acid to arachidonic acid (C20:4n-6) was higher in the subjects with higher MMP-
9 compared with the lower MMP-9 group (P < 0.001 for all).
Conclusion: So far, the evidence for an anti-inflammatory role of the n-3 PUFA has come from
dietary interventions. Our results were obtained from a free-living population and indicate that
there is a positive correlation between n-3 docosapentaenoic acid and MMP-9. What had triggered
the rise in MMP-9 is not known, since serum level of MMP-9 is raised in many inflammatory
conditions. These findings may indicate an increased biosynthesis of n-3 polyunsaturated fatty acids
in subclinical inflammation.
Background
As a consequence of arterial inflammation, serum MMP-9
is increased in primary arteritis [1,2] and in severe CAD
[3]. In addition to these processes, elevated serum MMP-
9 has been reported in cancer [4], asthma [5] and rheuma-
toid arthritis [6]. Thus, in inflammation in general there is
a rise of serum MMP-9 concentration.
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tant role in inflammation. The two classes of polyunsatu-
rated fatty acids (PUFA), the n-6 and n-3 series have
opposing physiological functions. Arachidonic acid
(20:4n-6), a metabolite of linoleic acid (18:2n-6), is the
substrate of cyclooxygenases and lipoxygenases in the pro-
duction of potent inflammatory eicosanoids. The polyun-
saturated fatty acids of the n-3 series (eicosapentaenoic
acid 20:5n-3, docosapentaenoic acid 22:5n-3, and
docosahexaenoic acid 22:6n-3) in turn inhibit the synthe-
sis of these mediators and produce eicosanoids with much
weaker effects [7,8]. As outlined above, the n-3 series is
considered as anti-inflammatory.
Low rates of CHD were found in Greenland Eskimos who
are exposed to a diet rich in n-3 fatty acid fish oil [9]. Such
diets have also been suggested to reduce the risk of inflam-
matory bowel disease [10]. Interestingly, some studies
have reported increased plasma n-3 polyunsaturated fatty
acid pattern in chronic inflammatory bowel diseases, such
as Crohn's disease and ulcerative colitis [11,12]. In fact,
significantly higher levels of docosapentaenoic acid
(22:5n-3) and lower levels of arachidonic acid (20:4n-6)
have been reported in serum of patients with long-stand-
ing Crohn's disease in comparison with controls [13].
Moreover, ileal and colonic fatty acids profiles in these
patients show a substantial increase of the highly polyun-
saturated fatty acids [14]. Patients with Crohn's disease
have also increased percentage of n-3 PUFA in peripheral
blood monocytes [15]. Rats with experimental ulcerative
colitis have increased n-3 fatty acids in colon mucosa [16].
These findings were suggested to indicate an increased
biosynthesis of polyunsaturated fatty acids in inflamma-
tion due to increased activity in the desaturase/elongation
enzymes by hitherto unknown mechanisms. With more
severe inflammation the essential fatty acids that are pre-
cursors to the polyunsaturated fatty acids are reduced, as
is observed in patients with rheumatoid arthritis [17] and
active colitis ulcerosa [11].
In this study we sought to clarify relationships of the levels
of arachidonic acid and the polyunsaturated n-3 fatty acid
compositions of isolated LDL, HDL2 and HDL3 particles
with MMP-9, a marker of inflammation.
Results
The subjects were divided into two groups: those with
higher and those with lower MMP-9 levels than the
median of 43 µg/l. The characteristics of the groups and
the arachidonic acid, eicosapentaenoic acid, docosapen-
taenoic acid and docosahexaenoic acid compositions of
LDL, HDL2 and HDL3 are shown in Tables I and II, respec-
tively. The background characteristics of the two groups
were very similar. The gender distribution was the same in
both groups. Mean values for age, BMI, total cholesterol,
triacylglycerol HDL or LDL cholesterol did not differ
between the two groups. Thus, these background variables
were not associated with serum MMP-9 concentrations.
When the polyunsaturated fatty acids were examined,
there was no difference between the groups in the propor-
tions of arachidonic acid, eicosapentaenoic acid, and
docosahexaenoic acid in the lipoprotein fractions. How-
ever, the mean percentage of docosapentaenoic acid in
LDL, HDL2 and HDL3 was significantly higher in the
group of subjects with the higher MMP-9 level in compar-
ison with those with the lower serum MMP-9 concentra-
tion (Table 2). Furthermore, the ratio of
docosapentaenoic acid to arachidonic acid in LDL, HDL2
and HDL3 was higher in subjects with higher MMP-9 than
in those with lower MMP-9 (p < 0.01 for all, data not
shown).
Table 1: Background characteristics of the MMP-9 subgroupsa
Group Ib n = 29 Group IIc n = 29 Significanced (p-value)
Sex (female/male) 16/13 16/13 1.000000
MMP9 (µg/l) 32.8 ± 5.1 53.8 ± 8.4 0.000000
Age (years) 38.6 ± 10.4 39.7 ± 11.1 0.70
BMI (kg/m2) 24.9 ± 4.0 23.9 ± 3.1 0.32
Cholesterol (mmol/l) 5.44 ± 0.81 5.48 ± 1.13 0.90
Triacylglycerol (mmol/l) 1.26 ± 0.66 1.44 ± 1.26 0.51
HDL-cholesterol (mmol/l) 1.65 ± 0.34 1.64 ± 0.42 0.90
LDL-cholesterol (mmol/l) 3.22 ± 0.77 3.25 ± 1.11 0.90
ApoA-I (g/l) 1.61 ± 0.21 1.56 ± 0.21 0.47
ApoB (g/l) 0.90 ± 0.20 0.89 ± 0.26 0.76
fB-Glucose (mmol/l) 4.5 ± 0.6 4.4 ± 0.5 0.36
aMeans ± SD are given; b MMP-9 <43 ug/l; c MMP-9 >43 ug/l; dMann-Whitney U-testPage 2 of 5
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Our result of a positive association between MMP-9 and
the percentage of docosapentaenoic acid in isolated lipids
of HDL and LDL may reflect increased metabolism of long
chain fatty acids in subclinical inflammation, analogous
to the situation seen in chronic non-active inflammatory
bowel disease [12-15]. Our subjects were subjectively
healthy, and the cause of variation of serum MMP-9 con-
centration remains unknown.
Docosapentenoic acid is one of the three major n-3 long
chain polyunsaturated fatty acids in fish and marine oils.
In addition to diet, eicosapentaenoic acid, docosapentae-
noic acid, and docosahexaenoic acid are obtained by syn-
thesis in the body from α-linolenic acid (18:3n-3)
through a series of desaturation and elongation reactions.
There is a possible explanation why increased synthesis of
n-3 fatty acids could lead to increase in docosapentaenoic
acid and not docosahexaenoic acid. It seems that docosap-
entaenoic acid is not easily further metabolized to docosa-
hexaenoic acid in the human body because the pathway
requires a rate-limiting ∆-6 desaturase reaction, chain
elongation and translocation of the resulting 24:6n-3 to
peroxisomes for oxidation [19]. N-3 fatty acids are often
treated as a unity, and the effects of docosapentaenoic acid
are rarely compared with those of eicosapentaenoic acid,
and docosahexaenoic acid. Therefore the functions of
docosapentaenoic acid are more poorly known.
Dietary supplementation with n-3 fatty acids has thought
to be of benefit in the management of inflammatory dis-
eases, because several studies have shown that n-3 fatty
acids can inhibit the synthesis and release of proinflam-
matory cytokines such as tumor necrosis factor alpha and
interleukin-1-β that are produced during inflammation
[20]. These cytokines increase MMP-9 synthesis and acti-
vation by inflammatory cells [21]. Therefore, it is possible
that a chronic inflammatory condition through increased
utilization of anti-inflammatory n-3 fatty acids leads to
increased activity of the biosynthesis of n-3 fatty acids.
These changes would be seen in all lipoprotein classes
through exchange of lipids.
Conclusion
In conclusion, our results indicate that there is a positive
correlation between n-3 docosapentaenoic acid and
MMP-9, a potential marker of inflammation. What had
triggered the rise in MMP-9 is not known. Together with
previous studies, our findings suggest an increased bio-
synthesis of n-3 polyunsaturated fatty acids in subclinical
inflammation.
Methods
Subjects
A total of 59 subjectively healthy 20 to 60 year-old women
(n = 32) and men (n = 27) were recruited amongst the per-
sonnel and students of Medical School of the University
Table 2: Percentages of PUFA in total fatty acids from separated lipoproteins in the MMP-9 subgroupsa
PUFAb Group Ic n = 29 Group IId n = 29 Significancee (p-value)
Arachidonic Acid
LDL-particles 5.61 ± 1.11 5.25 ± 0.87 0.25
HDL2-particles 7.02 ± 1.24 6.70 ± 1.18 0.43
HDL3-particles 7.86 ± 1.46 7.42 ± 1.13 0.28
Eicosapentaenoic Acid
LDL-particles 1.13 ± 0.39 1.25 ± 0.74 0.99
HDL2-particles 1.24 ± 0.40 1.37 ± 0.78 0.98
HDL3-particles 1.38 ± 0.43 1.50 ± 0.87 0.86
Docosapentaenoic Acid
LDL-particles 0.39 ± 0.08 0.47 ± 0.09 0.0015
HDL2-particles 0.63 ± 0.14 0.74 ± 0.14 0.0057
HDL3-particles 0.69 ± 0.15 0.80 ± 0.15 0.0080
Docosahexaenoic Acid
LDL-particles 2.13 ± 0.41 2.05 ± 0.62 0.35
HDL2-particles 3.49 ± 0.63 3.27 ± 0.92 0.16
HDL3-particles 3.66 ± 0.70 3.47 ± 0.97 0.21
aMeans ± SD are given; bPUFA, polyunsaturated fatty acids; cMMP-9 <43 ug/l;
dMMP-9 >43 ug/l; eMann-Whitney U-testPage 3 of 5
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participants filled a questionnaire, where emphasis was
given to their health status (diseases and use of medica-
tion) in addition to health related behavior (smoking, use
of alcohol and vitamins). All participants gave their writ-
ten consents to the study. The study protocol was
approved by the ethics committee of the Tampere Univer-
sity Hospital.
Laboratory methods
Blood samples were taken from the antecubital vein into
suitable tubes (Vacuette, Greiner) using minimal stasis
after a 12-hour fast while the subjects were seated (after a
15-min rest). Samples for the isolation of lipoproteins
were taken into EDTA-containing tubes, immediately
placed in ice, and plasma was separated after centrifuga-
tion (Heraeus, 2000 × g, + 4°C). EDTA-plasmas were sup-
plemented with sucrose (0.6% w/v final concentration).
All samples were kept frozen at -70°C until analyzed. Fast-
ing blood glucose concentration was determined from
capillary blood using Hemocue Glucose Analyzer
(Hemocue, Ängelholm Sweden).
Plasma cholesterol, HDL cholesterol, triacylglycerol,
apoA-I and apoB concentrations were measured with
Cobas Integra 700 automatic analyzer using reagents and
calibrators as recommended by the manufacturer (Roche
Diagnostic, Basel, Schwitzerland). LDL cholesterol was
calculated according to Friedewald.
For the accurate assessment of serum MMP-9, aliquots of
sera were removed and stored at -70°C in a freezer that
was not in daily use until analysis. Quantification of
immunoreactive MMP-9 was carried out by enzyme-
linked immunosorbent assay (ELISA) (Diabor Ltd, Oulu,
Finland). ELISAs were performed on 96-well microtiter
plates using standard protocols. Recombinant MMP-9
was used as standard. The microtiter plate was coated with
the monoclonal antibody (code GE-213). The bound pro-
teins from serum and standards were detected with a sec-
ondary polyclonal antibody produced in chicken against
MMP-9. A peroxidase-labeled anti-chicken-IgG (Chemi-
con, USA) was used for detection of the bound secondary
antibody. O-phenylenediamine (OPD) was used to visu-
alize the peroxidase label. The color formation was meas-
ured at 450 nm (Anhos 2000 microplate reader) and
calculations were done using a Multicalc program (Wal-
lac, Turku, Finland). The monoclonal antibody recog-
nized both the free MMP-9 and that bound to its
inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-
1) [2,18].
Lipoproteins were fractionated by isopycnic density gradi-
ent ultracentifugation. Two ml of plasma was mixed with
4.0 ml of d 1.35 g/l NaCl/KBr solution in a 14 × 95 mm
tube (Beckman, Palo Alto, USA) and then successively
overlayered with 4.5 ml of a d 1.006 salt solution and 1.0
ml of distilled water. For centrifugation a Beckman SW40
Ti rotor, at 36000 rpm for 40 hours in a Beckman L60 cen-
trifuge at 10°C was used. After ultracentrifugation the
contents of the tubes were fractionated with an Isco gradi-
ent fractionator (Model 640, Lincoln, USA). The 280 nm
absorbance of the effluent was continuously monitored
with an Isco UA-5 absorbance detector. The different lipo-
proteins were well separated by the resulting slightly curv-
ing salt gradient. The fractions belonging to LDL, HDL2
and HDL3 were pooled on the basis of the absorbance
curve.
The total fatty acid compositions of the ultracentrifugally
isolated LDL, HDL2 and HDL3 particles were analyzed by
gas-liquid chromatography. Lipids were extracted with
chloroform/methanol, partitioned and the chloroform
phase was dried under N2. The lipids were then hydro-
lyzed and transesterified with H2SO4 in dry methanol at
85°C for 2 h under N2. Following the addition of water,
methyl esters of the fatty acids were extracted with petro-
leum ether and analyzed in a Shimadzu GC-14A gas chro-
matograph (Shimadzu Corporation, Kyoto, Japan) with a
flame ionization detector using a Supelco SP 2560 capil-
lary column (100 m, 0.25 mm I.D., 0.20 µm film thick-
ness). The carrier gas was helium. The column
temperature was 180°C for 15 min, then programmed to
increase at 3°C/min to 230°C and held for 40 min. The
individual fatty acids were identified with the aid of a
standard mixtures of methyl esters (Lipid standards 189-
15 and 189-17, Sigma). The areas were measured with a
Shimadzu C-R4A Chromatopac Integrator and the results
expressed as percentages of the sum of all fatty acids from
14:0 to 22:6n-3. As a control sample we used a pool of iso-
lated HDL that was suitably diluted and kept frozen at -
70°C. The inter assay coefficient of variation for the per-
centage of different fatty acids ranged from 0.3 to 4.4 %.
Statistical analysis
Results are expressed as means ± standard deviation.
Plasma triacylglycerol concentrations were used as their
logarithms but reported as original results. Comparisons
were conducted by Mann-Whitney U-test. Univariate
associations between variables were analyzed using Spear-
man's correlation coefficients. The Statistica for Windows
(version 5.1) software package (Statsoft Inc., Oklahoma,
USA) was used for statistical analysis.
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